150 related articles for article (PubMed ID: 38188483)
1. Association of Programmed Cell Death 1 Inhibitor with Circumorificial Plasmacytosis.
Tanimu Y; Coombs R; Tanimu S; Onitilo A
Case Rep Oncol; 2024; 17(1):33-38. PubMed ID: 38188483
[TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab-Induced Acute Skin Reaction: A Case Report and Review of Literature.
Thomas M; Wazir A; Poudel A
Cureus; 2022 Jun; 14(6):e26143. PubMed ID: 35754442
[TBL] [Abstract][Full Text] [Related]
3. A multidisciplinary approach to treating a unique case of recurrent metastatic thymic carcinoma: case report.
Wang C; Erick Elkowitz D; Esposito MJ; Shah RD; Tannous H; Barilla-Labarca ML; Seetharamu N
Ther Adv Rare Dis; 2023; 4():26330040231190661. PubMed ID: 37576433
[TBL] [Abstract][Full Text] [Related]
4. Behcet's-like syndrome following pembrolizumab: An immune-related adverse event associated with programmed death receptor-1 inhibitor therapy.
Thomas S; Bae C; Joy-Ann T; Traverse W
J Oncol Pharm Pract; 2020 Jun; 26(4):995-999. PubMed ID: 31575354
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab-Induced Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a Case Report.
Siciliano MA; Dastoli S; d'Apolito M; Staropoli N; Tassone P; Tagliaferri P; Barbieri V
Front Oncol; 2020; 10():579445. PubMed ID: 33163407
[TBL] [Abstract][Full Text] [Related]
6. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
Gu YC; Liu Y; Xie C; Cao BS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
[TBL] [Abstract][Full Text] [Related]
7. Case report: Pharmacokinetics of pembrolizumab in a patient with stage IV non-small cell lung cancer after a single 200 mg administration.
de Vries F; Smit AAJ; Wolbink G; de Vries A; Loeff FC; Franssen EJF
Front Oncol; 2022; 12():960116. PubMed ID: 36713570
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab-induced severe oral mucositis in a patient with squamous cell carcinoma of the lung: A case study.
Yoon SY; Han JJ; Baek SK; Kim HJ; Maeng CH
Lung Cancer; 2020 Sep; 147():21-25. PubMed ID: 32652370
[TBL] [Abstract][Full Text] [Related]
9. Steroid-refractory dermatologic and pulmonary toxicity in a patient on rituximab treated with pembrolizumab for progressive urothelial carcinoma: a case report.
Hines J; Daily E; Pham AK; Shea CR; Nadeem U; Husain AN; Stadler WM; Reid P
J Med Case Rep; 2021 Mar; 15(1):124. PubMed ID: 33736690
[TBL] [Abstract][Full Text] [Related]
10. Case report: reinitiating pembrolizumab treatment after small bowel perforation.
Beck TN; Kudinov AE; Dulaimi E; Boumber Y
BMC Cancer; 2019 Apr; 19(1):379. PubMed ID: 31018834
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab-Induced Lichen Planus in a Patient With Non-Small-Cell Lung Carcinoma (NSCLC) That Correlates to Therapeutic Response.
Sehbai A; Hamid MA; Ibrahim Z
Cureus; 2022 Nov; 14(11):e31454. PubMed ID: 36523676
[TBL] [Abstract][Full Text] [Related]
12. Late-onset programmed cell death protein-1 inhibitor-induced pneumonitis after cessation of nivolumab or pembrolizumab in patients with advanced non-small cell lung cancer: a case series.
Kimura H; Sone T; Araya T; Murata A; Yamamura K; Ohkura N; Hara J; Abo M; Kasahara K
Transl Lung Cancer Res; 2021 Mar; 10(3):1576-1581. PubMed ID: 33889531
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary pleomorphic carcinoma in an elderly patient treated with pembrolizumab shows a marked response.
Yamasaki M; Matsumoto Y; Nakamoto K; Hattori N
J Cancer Res Ther; 2021; 17(6):1580-1582. PubMed ID: 34916402
[TBL] [Abstract][Full Text] [Related]
14. Multiple autoimmune side effects of immune checkpoint inhibitors in a patient with metastatic melanoma receiving pembrolizumab.
Kethireddy N; Thomas S; Bindal P; Shukla P; Hegde U
J Oncol Pharm Pract; 2021 Jan; 27(1):207-211. PubMed ID: 32390537
[TBL] [Abstract][Full Text] [Related]
15. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance.
Bhardwaj M; Chiu MN; Pilkhwal Sah S
Cutan Ocul Toxicol; 2022 Mar; 41(1):73-90. PubMed ID: 35107396
[TBL] [Abstract][Full Text] [Related]
16. Delayed immune-related neutropenia with hepatitis by pembrolizumab.
Nakako S; Nakashima Y; Okamura H; Tani Y; Ueda T; Makuuchi Y; Kuno M; Takakuwa T; Nishimoto M; Koh H; Nakamae H; Hino M
Immunotherapy; 2022 Feb; 14(2):101-105. PubMed ID: 34758635
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab combined with stereotactic body radiotherapy in a patient with human immunodeficiency virus and advanced non-small cell lung cancer: a case report.
Li D; He C; Xia Y; Du Y; Zhang J
J Med Case Rep; 2018 Apr; 12(1):104. PubMed ID: 29681240
[TBL] [Abstract][Full Text] [Related]
18. Pericardial effusion with pembrolizumab.
Fernández Madrigal L; Montero Pérez O; Rodriguez Garcés MY; Inoriza Rueda Á; Martínez Marcos FJ
J Oncol Pharm Pract; 2022 Oct; 28(7):1664-1670. PubMed ID: 35133214
[TBL] [Abstract][Full Text] [Related]
19. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.
Naing A; Wong DJ; Infante JR; Korn WM; Aljumaily R; Papadopoulos KP; Autio KA; Pant S; Bauer TM; Drakaki A; Daver NG; Hung A; Ratti N; McCauley S; Van Vlasselaer P; Verma R; Ferry D; Oft M; Diab A; Garon EB; Tannir NM
Lancet Oncol; 2019 Nov; 20(11):1544-1555. PubMed ID: 31563517
[TBL] [Abstract][Full Text] [Related]
20. Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression.
Isshiki T; Isobe K; Tochigi N; Sunakawa M; Nakamura Y; Shibuya K; Sakamoto S; Takai Y; Homma S
Case Rep Oncol; 2018; 11(3):688-692. PubMed ID: 30483099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
